



July 12, 2022
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Structure for Promoting Sustainability

July 12 - JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that its Board of Directors resolved at a meeting today to establish the Sustainability Advisory Committee, Sustainability Committee, and Environment Committee as key functions in the framework for promoting sustainability.

1. Purpose

JCR strives to attain sustainability in the form of a sustainable society and sustainable growth of the Company through business activities based on its corporate philosophy of “contributing toward people’s healthcare through pharmaceutical products.” The Company therefore established the following committees to enable in-depth discussions and formulating strategies in close alignment with management in response to the ever-changing social and business environment and challenges. As we embrace innovation (or new technology) and creative mindset of all employees, JCR will continue to work as one team, driven by a sense of purpose in the rare disease field, to pursue sustainability in the manner unique to JCR.

2. Role and Composition of Committees

Name	Role and Composition
Sustainability Advisory Committee	Members will be internal directors, independent outside directors, and full-time Audit & Supervisory Board members. This Committee will provide feedback on matters presented to the Board of Directors by the Sustainability Committee.
Sustainability Committee	Chaired by the director in charge of sustainability, members will be employees appointed from each business division. This Committee will identify material issues, discuss, and propose ESG-related initiatives, monitor progress of initiatives, and report findings to the Board of Directors.
Environmental Committee	Members will be internal directors and employees appointed from each business division. They will consider the environmental impact of JCR’s business activities as a long-term risk factor affecting business, environment, and society, and promote the practice of environment-friendly business activities.

3. Date of Establishment

July 12, 2022

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 47-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

###